MDxHealth SA (MDXH) Stock Forecast
MDXH analyst forecast
as of October 17, 2026- Analyst consensus
- Buy 4.33 / 5 from 6 analysts
- Price target
- $1.12 average of analyst targets
- Upside to target
- +443.5% from the latest close
- Next earnings
- November 11, 2026 EPS estimate $-0.07
- 52-week range
- $0.21 – $5.00
MDXH analyst ratings
6 analystsNumber of analysts at each rating.
MDXH price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
MDXH earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.09 | −$0.11 | −$0.06 | −$0.16 | +42.5% | 5 |
| Current fiscal year (2026) | −$0.46 | −$0.46 | −$0.46 | −$0.43 | −6.3% | 1 |
| Next fiscal year (2027) | −$0.38 | −$0.38 | −$0.38 | −$0.46 | +17.4% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
MDXH revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $25.0M | $23.0M | $26.2M | +5.9% | 6 |
| Current fiscal year (2026) | $97.1M | $94.2M | $100.7M | +6.2% | 6 |
| Next fiscal year (2027) | $109.9M | $104.0M | $115.5M | +13.2% | 6 |
MDXH EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
MDXH revenue: reported and forecast
MDXH EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.16 | −$0.10 | −$0.09 | −$0.09 | −$0.09 | −43.2% | 5 up · 0 down |
| Current fiscal year (2026) | −$0.32 | −$0.46 | −$0.46 | −$0.46 | −$0.46 | +43.8% | 0 up · 1 down |
| Next fiscal year (2027) | −$0.13 | −$0.38 | −$0.38 | −$0.38 | −$0.38 | +192.3% | 0 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
MDXH earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; MDXH beat in 1 of 12.
What analysts expect from MDXH
6 analysts cover MDxHealth; their consensus rating is buy (4.33 on a 1–5 scale, where 5 is a strong buy). The average price target is $1.12, 443.5% above the latest close of $0.21. Analysts expect earnings of −$0.46 per share for 2026, −6.3% from a year earlier. For 2027 the average estimate is −$0.38 per share on revenue of $109.9 million. MDxHealth beat the EPS estimate in 1 of the last 12 quarters.
Related: MDXH income statement, MDXH key metrics, MDXH chart. See the MDXH stock overview for the latest quote and news.
MDXH forecast FAQ
What is MDxHealth's price target?
The average analyst price target for MDxHealth is $1.12, 443.5% above the latest close of $0.21.
Is MDxHealth a buy, hold or sell?
Of 6 analysts covering MDxHealth, 4 rate it a strong buy, 0 a buy, 2 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is MDxHealth's EPS forecast?
Analysts forecast −$0.46 per share for 2026 (range −$0.46 to −$0.46); for 2027 the estimate is −$0.38.
What is MDxHealth's revenue forecast?
The average revenue estimate for 2026 is $97.1 million, growth of 6.2%; for 2027 it is $109.9 million.
When does MDxHealth report earnings?
MDxHealth is expected to report results for the quarter ending September 30, 2026 on November 11, 2026; the EPS estimate is $-0.07.
Does MDxHealth usually beat earnings estimates?
MDxHealth reported EPS at or above the analyst estimate in 1 of the last 12 quarters.